Safety and efficacy of sofosbuvir/ledipasvir and sofosbuvir/daclatasvir in the treatment of hepatitis C in patients with decompensated cirrhosis.

Autor:	El Kassas M; Endemic Medicine Department, Faculty of Medicine, Helwan University, Cairo., Abdeen N; Tropical medicine, Faculty of Medicine, Alexandria University, Alexandria., Omran D; Endemic Medicine and Hepatology Department, Faculty of Medicine, Cairo University., Alboraie M; Department of Internal Medicine, Al-Azhar University., Salaheldin M; Tropical Medicine Department, Faculty of Medicine, Ain Shams University, Cairo., Eltabbakh M; Tropical Medicine Department, Faculty of Medicine, Ain Shams University, Cairo., Farghaly R; Department of community medicine, Faculty of Medicine, Suez Canal University., Emadeldeen M; Hepatogastroenterology Department, National Hepatology & Tropical Medicine Research Institute, Cairo., Afify S; Hepatogastroenterology Department, National Hepatology & Tropical Medicine Research Institute, Cairo., Sweedy A; Gastroenterology Department, Damietta Cardiology and Gastroenterology Center, Damietta., Ghalwash A; Hepatology and Gastroenterology Department, AGOZA Police Hospital, Cairo., Abbass A; Hepatology and Gastroenterology Department, AGOZA Police Hospital, Cairo., Ezzat S; Epidemiology and Preventive Medicine Department, National Liver Institute, Menoufia University, Menoufia, Egypt., Tahoon M; Epidemiology and Preventive Medicine Department, National Liver Institute, Menoufia University, Menoufia, Egypt., ELshazly HM; Hepatology and gastroenterology department, national liver institute.Menoufia University, Egypt., Hamdy H; Tropical Medicine Department, Faculty of Medicine, Ain Shams University, Cairo., Omar H; Endemic Medicine and Hepatology Department, Faculty of Medicine, Cairo University.
Jazyk:	angličtina
Zdroj:	European journal of gastroenterology & hepatology [Eur J Gastroenterol Hepatol] 2021 Dec 01; Vol. 33 (1S Suppl 1), pp. e877-e882.
DOI:	10.1097/MEG.0000000000002287
Abstrakt:	Background: Hepatitis C virus (HCV)-related decompensated cirrhosis is a severe life-threatening illness. The safety of direct-acting antivirals (DAAs) has opened a gate of hope for that subgroup of patients who were previously contraindicated for interferon therapy. Objective: We aimed at the investigation of the safety and efficacy of different DAAs regimens in the treatment of HCV-related decompensated cirrhosis patients, to determine sustained virological response (SVR)12 rates and to analyze the factors associated with response. Methods: A retrospective, single-center study including HCV-related decompensated cirrhosis patients who received DAAs. Demographic, laboratory and clinical data were analyzed. The SVR12 rate was the primary outcome measure. Secondary outcomes included the predictors of response, changes in the baseline model for end-stage liver disease and child-turcotte-pugh (CTP) scores, and fibroindices (APRI and fibrosis-4 index) at 12 weeks after treatment. Results: In total, 145 eligible patients (141 with CTP class B and 4 with class C) were enrolled in this study. SVR12 was achieved by 88.06% (118/134) of efficacy population on different DAAs regimens, Treatment was discontinued in 11 patients because of severe side effects without any deaths. Younger age showed a significant positive association with SVR12. Conclusions: DAAs can be used for the treatment of HCV-related decompensated liver disease, with acceptable SVR12 rates and safety profiles. (Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu